Grockowiak, Elodie
Korn, Claudia
Rak, Justyna
Lysenko, Veronika http://orcid.org/0000-0002-6886-5444
Hallou, Adrien http://orcid.org/0000-0002-3162-7848
Panvini, Francesca M.
Williams, Matthew
Fielding, Claire
Fang, Zijian
Khatib-Massalha, Eman
García-García, Andrés http://orcid.org/0000-0002-8797-649X
Li, Juan
Khorshed, Reema A.
González-Antón, Sara
Baxter, E. Joanna
Kusumbe, Anjali
Wilkins, Bridget S.
Green, Anna
Simons, Benjamin D. http://orcid.org/0000-0002-3875-7071
Harrison, Claire N.
Green, Anthony R.
Lo Celso, Cristina http://orcid.org/0000-0002-1163-4207
Theocharides, Alexandre P. A. http://orcid.org/0000-0002-1535-8692
Méndez-Ferrer, Simón http://orcid.org/0000-0002-9805-9988
Funding for this research was provided by:
EC | Horizon 2020 Framework Programme (ERC-2014-CoG-648765)
Cancer Research UK (C61367/A26670)
RCUK | MRC | Medical Research Foundation (MR/V005421/1)
Article History
Received: 27 July 2022
Accepted: 27 June 2023
First Online: 7 August 2023
Competing interests
: C.N.H. reports funded research from Novartis; speaker fees from Novartis, Janssen, CTI, Celgene and Medscape; and advisory board membership for Incyte, CTI, Sierra Oncology, Novartis, Celgene, Roche, AOP Pharma, Geron and AstraZeneca. A.G. reports speaker fees from Novartis and Bristol Myers Squibb. The other authors declare no competing interests.